HFS
URGN icon

Hughes Financial Services’s UroGen Pharma URGN Stock Holding History

Hughes Financial Services’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$110 Hold
3
– – ﹤0.01% 1420
2026
Q1 		$54 Buy
+3
New +$60 ﹤0.01% 1434

Other funds holding URGN

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Hughes Financial Services's URGN Position: Q2 2026 in Review

Hughes Financial Services held its UroGen Pharma (URGN) position steady in Q2 2026 at 3 shares worth $110. The position accounts for ﹤0.01% of the portfolio, ranked #1420.

Hughes Financial Services first reported a position in URGN in Q1 2026 and has held it in 2 quarters since. 190 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

  • Hughes Financial Services held 3 shares of UroGen Pharma worth $110 as of Q2 2026.
  • Hughes Financial Services left its UroGen Pharma share count unchanged in Q2 2026.
  • UroGen Pharma made up ﹤0.01% of Hughes Financial Services's portfolio in Q2 2026, its #1420 holding.
  • Hughes Financial Services first reported a position in UroGen Pharma in Q1 2026 and has held it in 2 quarters since.
  • 190 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Hughes Financial Services's 13F filing for Q2 2026, filed 20 Jul 2026.